Comparative Pharmacology
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus CARTEOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXOLOL HYDROCHLORIDE versus CARTEOLOL HYDROCHLORIDE.
BETAXOLOL HYDROCHLORIDE vs CARTEOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
10-20 mg orally once daily; maximum 20 mg/day.
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
None Documented
None Documented
Terminal elimination half-life: 14–22 hours (mean 16 hours); sufficient for once-daily dosing in hypertension; prolonged in renal impairment.
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment.
Renal: 80% (as unchanged drug and inactive metabolites), Fecal: 20%
Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%).
Category C
Category C
Beta-Blocker
Beta-Blocker